Niu et al. used [64Cu]DOTA‐trastuzumab to monitor HER2 degradation with therapy treatment in a human ovarian cancer model in mice.23 The tumour uptake was significantly different between the control and the treatment groups, 33.9 ± 7.82 versus 11.74 ± 4.23% ID/g 24 h post injection. This evidence concerns the gene ERBB2 and neoplasm.